Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Julio C. Chavez, MD, MS
Articles
EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma
July 29th 2025Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.
Read More
EHA 2025: GOLCA Plus Rituximab Shows Promise in R/R DLBCL
July 28th 2025Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
